Incruse ellipta and Laryngitis - a phase IV clinical study of FDA data

Summary:

Laryngitis is reported as a side effect among people who take Incruse ellipta (umeclidinium bromide), especially for people who are female, 60+ old, also take Symbicort, and have Chronic obstructive pulmonary disease.

The phase IV clinical study analyzes which people have Laryngitis when taking Incruse ellipta. It is created by eHealthMe based on reports of 8,447 people who have side effects when taking Incruse ellipta from the FDA, and is updated regularly.

What is Incruse ellipta?

Incruse ellipta has active ingredients of umeclidinium bromide. eHealthMe is studying from 8,485 Incruse ellipta users. Check the latest studies of Incruse ellipta.

What is Laryngitis?

Laryngitis (inflammation of the larynx) is found to be associated with 938 drugs and 823 conditions by eHealthMe. Check the latest studies of Laryngitis.

On Jul, 13, 2026

8,447 people reported to have side effects when taking Incruse ellipta.
Among them, 17 people (0.2%) have Laryngitis.

Among these 17 people:

What is the gender of people who have Laryngitis when taking Incruse ellipta? *

female: 81.25 %
male: 18.75 %

What is the age of people who have Laryngitis when taking Incruse ellipta? *

What are other drugs people take besides Incruse ellipta? *

What are other side effects people have besides Laryngitis? *

Nasopharyngitis (inflammation of the nasopharynx): 5 people, 29.41%
Hoarseness Or Changing Voice: 5 people, 29.41%
Mobility Decreased (ability to move is reduced): 3 people, 17.65%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 3 people, 17.65%
Fatigue (feeling of tiredness): 3 people, 17.65%
Cough: 3 people, 17.65%
Fall: 3 people, 17.65%
Asthma: 3 people, 17.65%
Bronchitis (inflammation of the mucous membrane in the bronchial tubes): 3 people, 17.65%
Cerebral Atrophy (decrement in size of brain): 2 people, 11.76%

What are the existing conditions these people have? *

Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 7 people, 41.18%
Asthma: 4 people, 23.53%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 17.65%
Pain: 3 people, 17.65%
Stress And Anxiety: 3 people, 17.65%
Vitamin B12 Decreased: 2 people, 11.76%
Depression: 2 people, 11.76%
Dizziness: 2 people, 11.76%
Dry Eyes (lack of adequate tears): 2 people, 11.76%
Enlarged Heart: 2 people, 11.76%

* Approximation only. Some reports may have incomplete information.

Do you take Incruse ellipta and have Laryngitis?

- Check whether Laryngitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Incruse ellipta:

Incruse ellipta (8,485 reports)

Laryngitis treatments and more:

Laryngitis (13,270 reports)

Browse all side effects of Incruse ellipta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Laryngitis:

Laryngitis (938 drugs)

Browse all the conditions that are associated with Laryngitis:

Laryngitis (823 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on umeclidinium bromide (the active ingredients of Incruse ellipta) and Incruse ellipta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.